HPV is the most common sexually transmitted infection. Globally there areapproximately 330 million women presently infected with HPV, with 70% ofexisting infections in Asian populations. The virus infects the skin andmucous membranes. There are more than 30 important HPV types that can infectthe genital areas of men and women, including the skin of the penis, vulva(area outside the vagina), and anus, and the linings of the vagina, cervix,and rectum. Most people who become infected with certain types of HPV do noteven know they have it. Cervical cancer, in which malignant cells form in thetissue of the cervix, is third leading cancer in women and the second leadingcause of cancer deaths in women worldwide. It is well known that certain HPVtypes are the primary cause of cervical cancer. If HPV infection is detectedearly, cervical cancer could be preventable. Early diagnosis of HPV infection,which could lead to cervical cancer, is recommended for every woman.

According to recent clinical trial assessments, it was reported in MedicalNews Today that the global market for HPV testing is projected to be$250 million in 2008, with the total available market valued at $1 billion.There are more than 10 million HPV tests being performed annually in theUnited States alone, with only 28% market penetration. According to the 2007CIA Factbook, in China there are approximately 455 million women between theages of 15 and 64 years old. In China alone, at an extremely conservativeestimate of 1 million possible patients, with HPV screening at a cost ofapproximately $50, there is a $50 million annual market potential for HPVtesting in China. Estimates indicate that HPV testing in China could grow fromapproximately 16 million tests in 2009 to over 25 million by 2025.

Mr. Gary Dreher, CEO of AMDL, noted that "this HPV Diagnostic Test Kit isanticipated to become a major product for the Company. This sublicenseagreement demonstrates AMDL's capability to in-license state of the artdiagnostic products that can gain swift regulatory approval and marketacceptance." Dr. Tyler McCabe, President and CEO of MGI indicated, "In Chinaalone, with skillful effort, substantial sales potential could be realizedwithin a few years. MGI is excited about the potential of this relationship,due to AMDL's infrastructure in China and certain Asian countries, and we lookforward to working together to enter this large market."

About Jade Pharmaceutical: JPI has access to the fastest growingpharmaceutical and consumer market in the world: China. AMDL, through itssubsidiaries, JPI currently manufactures large volume injection fluids,tablets and other related products, holding licenses for 133 products. It alsomanufactures 107 generic, over the counter and supplemental pharmaceuticalproducts under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtainedat http://www.amdl.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. Such statements aresubject to certain risks and uncertainties, and actual circumstances, eventsor results may differ materially from those projected in such forward-lookingstatements. The Company cautions readers not to place undue reliance on anyforward-looking statements. The Company does not undertake, and specificallydisclaims any obligation, to update or revise such statements to reflect newcircumstances or unanticipated events as they occur.

Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 VoiceMail: 714.505.4460SOURCE AMDL, Inc.